Investors Sell Qiagen (QGEN) on Strength (QGEN)

Investors sold shares of Qiagen NV (NASDAQ:QGEN) on strength during trading on Tuesday. $9.99 million flowed into the stock on the tick-up and $122.03 million flowed out of the stock on the tick-down, for a money net flow of $112.04 million out of the stock. Of all stocks tracked, Qiagen had the 5th highest net out-flow for the day. Qiagen traded up $0.55 for the day and closed at $32.21

A number of brokerages recently weighed in on QGEN. Zacks Investment Research upgraded shares of Qiagen from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research note on Tuesday, October 10th. Cowen restated a “hold” rating and set a $33.00 price objective on shares of Qiagen in a research note on Friday, November 3rd. Commerzbank restated a “buy” rating on shares of Qiagen in a research note on Tuesday, November 7th. BidaskClub upgraded shares of Qiagen from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Finally, DZ Bank reiterated a “neutral” rating on shares of Qiagen in a research report on Tuesday, December 19th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $34.63.

The company has a debt-to-equity ratio of 0.68, a current ratio of 5.33 and a quick ratio of 4.78. The stock has a market cap of $7,440.00, a PE ratio of 82.59, a P/E/G ratio of 1.80 and a beta of 1.10.

Qiagen (NASDAQ:QGEN) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, hitting the consensus estimate of $0.32. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The firm had revenue of $364.00 million for the quarter, compared to analysts’ expectations of $363.42 million. During the same period in the previous year, the business earned $0.29 earnings per share. Qiagen’s revenue for the quarter was up 7.5% compared to the same quarter last year. analysts expect that Qiagen NV will post 1.25 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Oppenheimer Asset Management Inc. increased its stake in Qiagen by 0.5% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock worth $133,000 after purchasing an additional 20 shares in the last quarter. M&T Bank Corp increased its stake in Qiagen by 2.7% in the 2nd quarter. M&T Bank Corp now owns 8,155 shares of the company’s stock worth $273,000 after purchasing an additional 215 shares in the last quarter. Quadrant Capital Group LLC increased its stake in Qiagen by 4.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock worth $183,000 after purchasing an additional 225 shares in the last quarter. QS Investors LLC increased its stake in Qiagen by 1.7% in the 2nd quarter. QS Investors LLC now owns 13,594 shares of the company’s stock worth $456,000 after purchasing an additional 226 shares in the last quarter. Finally, Acrospire Investment Management LLC increased its stake in Qiagen by 11.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock worth $112,000 after purchasing an additional 349 shares in the last quarter. Hedge funds and other institutional investors own 62.09% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/investors-sell-qiagen-qgen-on-strength-qgen/1821583.html.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.